Industry News

The oral granules can be sprinkled on food, providing a new administration option for those who have difficulty swallowing

The agency seeks public feedback on diversifying perspectives and streamlining committee processes.

Novartis could shell out up to $2.7 billion in a quest to expand its radioligand pipeline

Tivdak is the first ADC with demonstrated overall survival data to be granted full FDA approval in this patient population

Xolremdi is the first therapy specifically indicated for patients with WHIM

The novel mGluR2 PAM medication failed to delay the time for patients to reach baseline seizure count

The new 'Advanced Research Center' is part of a $1.6 billion investment initiative at the company's Darmstadt site

Beqvez, priced at $3.5 million, is now tied with CSL's hemophilia therapy as the second most expensive drug in the world

The "strategic productivity initiative" is designed to drive $1.5 billion in cost savings by the end of 2025

The partners will develop in vivo CRISPR-based gene editing therapies in a deal that could reach $470 million

Led by Genentech's former CSO, Xaira is betting on the application of computational methods to drug design

The radioligand therapy is the first FDA approved treatment specifically for children with gastroenteropancreatic neuroendocrine tumors

Anktiva is the first IL-15 superagonist approved for non-muscle invasive bladder cancer

Facing exploding demand for its weight loss and diabetes drugs, Lilly grabs up a Wisconsin facility

Incyte will pick up two potential first-in-class oral MRGPR antagonists in a deal worth $750 million

The pact grants Ipsen the option to acquire the rights to two candidates pursued under the collaboration

As part of the $380 million deal, Cellares will tech-transfer BMS CAR T-cell therapies onto its fully automated manufacturing platform

Alecensa is now the first and only ALK inhibitor approved for people with ALK-positive early-stage NSCLC following tumor resection

The NaV1.8 inhibitor also nabbed Breakthrough Therapy designation for diabetic peripheral neuropathy pain

The drugmaker shared positive late-stage trial results for its D1/D5 receptor in Parkinson’s disease

The oncology biotech could receive $1.2 billion in milestone payments and royalties on future sales

The drugmaker shared that the trials demonstrated a reduction of up to 63% in the apnea-hypopnea index

Gepotidacin, a potential first-in-class oral antibiotic, is already armed with two positive trials in UTIs

In a phase 3 trial, Columvi plus chemo improved survival rates for patients with relapsed or refractory diffuse large B-cell lymphoma

Fabhalta heads towards another indication with a phase 3 win in rare kidney disease

The UK-based biotech received notice that the 2021 deal will be terminated in 180 days

The review began in July 2023, after two patients in Iceland reported adverse events

The cell culture facility expansion will add large-scale production capacity as well as generate an additional 680 jobs by 2031

The judge said Lilly was attempting to use state laws to enforce federal regulations, which is the responsibility of the FDA

Key to the deal is Alpine’s lead molecule, a dual BAFF/APRIL antagonist in phase 3 trials for kidney disease